Triple-negative breast cancer (TNBC) is defined by the lack of expression of human epidermal growth factor receptor 2 (HER-II), estrogen receptors (ER), and progesterone receptors (PR), which limits the effectiveness of receptor-targeted treatments and complicates both diagnosis and therapeutic intervention [3,4]. The gene discussed is PGR; the disease is triple-negative breast carcinoma.